The U.S. IPO market in 2026 is exhibiting pronounced structural divergence. Against the backdrop of a broad pullback in newly listed AI-related stocks, the biotech sector has emerged as the primary destination for capital allocation, supported by solid industry fundamentals, active merger and acquisition activity, and notable individual stock gains.
Data show that year-to-date in 2026, the weighted average return for U.S. biotech and pharmaceutical IPOs stands at 55%, while the overall U.S. IPO market, excluding special purpose acquisition companies and other financial instruments, posts a weighted average loss of 4.4%. This robust performance is accelerating the pace of listings. So far this month alone, at least six biotech companies have filed IPO applications, including Scribe Therapeutics, which focuses on CRISPR gene-editing therapies. These companies are expected to complete their listings by late July to early August, securing funding before the traditional summer lull. Jack Bannister, Senior Managing Director of Equity Capital Markets at investment bank Leerink Partners, described this as the healthiest biotech IPO market in recent years.
Market consensus earlier anticipated that 2026 would be a landmark year for IPOs in AI, aerospace, and defense, with particular attention on SpaceX’s potential record-breaking offering. However, as investors have grown concerned over stretched valuations in the AI space, the weighted average post-IPO decline for the ten largest U.S. offerings this year has reached 6.3%, signaling a clear dampening of enthusiasm for AI new issues. In stark contrast, the biotech sector continues to attract sustained capital inflows. Key drivers behind the sector’s outperformance include a roughly 13% year-to-date gain in the Nasdaq Biotechnology Index (NBI), a stabilizing regulatory environment, positive clinical trial breakthroughs, and continued merger and acquisition activity by large pharmaceutical companies.
Over the past month, the industry has witnessed three major acquisition transactions each exceeding $10 billion, including AbbVie’s (ABBV) purchase of Apogee Therapeutics, GlaxoSmithKline’s (GSK) acquisition of Nuvalent, and Vertex Pharmaceuticals’ (VRTX) takeover of Crinetics Pharmaceuticals. These deals have not only lifted overall sector valuations but have also provided investment institutions with substantial exit proceeds, which are being recycled back into the IPO market. Seth Rubin, Global Head of Equity Capital Markets at Stifel Financial, noted that a number of large global funds are currently increasing their allocation to the healthcare sector, while the strong returns from small- and mid-cap biotech names have further bolstered investor confidence in the industry.
Data indicate that, as of now, the number of biotech IPOs in the U.S. in 2026 has already surpassed the full-year 2025 total of just eight. Nevertheless, compared with the peak period of 2020–2021, when more than 200 companies went public during the pandemic, the current market remains in a relatively rational recovery phase. Rubin stated that the market is not showing signs of significant overheating, and the overall financing pace remains healthy. In terms of fundraising scale, total proceeds from U.S. biotech IPOs this year have exceeded $5 billion, roughly triple last year’s figure.
